Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome

Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome

LO2A showed efficacy in improving key measures of dry eye in patients with Sjögren’s; Wize is currently enrolling patients in a Phase IV study in this indication HOD HASHARON, Israel, May 22, 2018 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company